Navigation Links
Exosome Diagnostics Names Kapil Dhingra Chairman of the Board of Directors
Date:4/29/2013

NEW YORK, April 29, 2013 /PRNewswire/ -- Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic tests for use in personalized medicine, today announced that Kapil Dhingra, M.D., has been named chairman of Exosome Diagnostics Board of Directors. 

Dr. Dhingra, 52, has served as a member of Exosome's board of directors since March 2012.  He has significant experience transforming oncology therapeutic and diagnostic development programs into products available to physicians and patients.  He is managing member of KAPital Consulting, a healthcare consulting firm he founded in 2008, which provides oncology-related strategic consulting services to biopharmaceutical companies.  From 1999-2008, he served in positions of increasing responsibility at Hoffmann-La Roche, Inc, including vice president, head, Oncology Disease Biology Leadership team and Head, Oncology Clinical Development. Before joining Roche, he worked at Eli Lilly & Co, and on the faculty of The University of Texas MD Anderson Cancer Center.  During his tenures at both Eli Lilly and Hoffmann-LaRoche, Dr. Dhingra maintained an active academic career first as a clinical associate professor at Indiana University School of Medicine and most recently as a Clinical Affiliate at Memorial Sloan Kettering Cancer Center.  Dr. Dhingra also serves on several emerging life science company boards. He previously served on the Boards of several successful companies, including Biovex, Micromet and YM Biosciences, that were acquired by major pharmaceutical companies.  He received his medical training from the All India Institute of Medical Sciences.

"Dr. Dhingra has been a critical contributor to the company since he was first appointed to our Board of Directors last year," said James McCullough , chief executive officer of Exosome Diagnostics. "As we transition toward commercialization in the life sciences and clinical diagnostics markets, we are fortunate to have Dr. Dhingra deep industry experience."

Dr. Dhingra stated, "I am pleased to be asked by the Board to take over as Chairman at this important juncture in the evolution of this company.  Exosome Diagnostics has built a truly exciting platform with the potential to transform the practice of medicine across a variety of therapeutic areas.   I have very much enjoyed working with the Board and the executive team over the past year.   The enormous progress achieved by the company in such a short time has further convinced me that the ability to detect molecular alterations in DNA and RNA contained in the exosomes will play a major role in the future of personalized medicine."

About Exosome Diagnostics
Exosome Diagnostics is a leading developer of biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes are packaged and shed into all biofluids, including blood, urine and CSF, providing a stable source for intact, cell-specific nucleic acids. The Company's proprietary exosome diagnostic technology makes use of the presence and natural stability of RNA in exosomes to detect and measure levels of genes responsible for cancer and other diseases. The Company is developing in vitro diagnostic products for use in companion diagnostic applications, detection, and real-time monitoring of disease. The Company maintains facilities in New York, St. Paul, MN and Munich, Germany. For more information, please visit www.exosomedx.com.


'/>"/>
SOURCE Exosome Diagnostics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics
2. Accelerate Brain Cancer Cure and Exosome Diagnostics Collaborate to Advance Clinical Studies of Exosome Biofluid Molecular Diagnostics Technology in Brain Cancer
3. Exosome Diagnostics Presents Data at American Urology Association Demonstrating Potential Utility of Urine Exosomes to Non-invasively Detect and Manage Prostate Cancer
4. ResearchMoz.us: MicroRNAs and Exosomes Market Report 2012 - Industry Research Report
5. Quest Diagnostics CE Marks Simplexa™ Test for Cytomegalovirus for Sale in Europe
6. SuperNova Diagnostics® to Present at the 23rd Annual Piper Jaffray Healthcare Conference in New York City
7. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
8. S.E.D. Labs to be Acquired by Quest Diagnostics
9. SuperNova Diagnostics® to Present at Biotech Showcase™ 2012 During JP Morgan Healthcare Conference January 9 - 12
10. Exagen Diagnostics Launches Cutting-Edge Lupus Diagnostic
11. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... DIEGO , June 27, 2016  Sequenom, Inc. ... committed to enabling healthier lives through the development of ... Court of the United States ... courts that the claims of Sequenom,s U.S. Patent No. ... patent eligibility criteria established by the Supreme Court,s Mayo ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, former ... of the University of North Carolina Kenan-Flagler Business School effective June ... UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes and ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The ... is proud to add Target to its list of well-respected retailers. This list ...
Breaking Biology Technology:
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
Breaking Biology News(10 mins):